News

The chief medical officer of Wave Life Sciences provided insight into the investigational DMD treatment.

The Senior Medical Director at Eli Lilly discussed the clinical impact galcanezumab could have for patients with cluster headache if approved by the FDA.

A middle-aged man explains that his seizures occur almost daily, and he suggests that either diazepam or the recently approved cannabis (CBD) medication would help control them.

Presenting our year in review, a collection by experts in their respective fields of brain injury, MS, concussion, epilepsy, migraine, and more.

The director of the epilepsy center at Cleveland Clinic spoke about the process that leads to the selection of candidacy for deep brain stimulation.

The therapy met both primary and secondary end points across a broad spectrum of patients with generalized myasthenia gravis, including significant reductions in both QMG and MG-ADL scores.

Pharmacokinetic data from phase 1 studies of AXS-05 showed it increases dextromethorphan concentrations into a potential therapeutic range. It was granted a Fast Track designation.

The director of the Epilepsy Center at Children's Health spoke about the findings of the clinical screening program, and how depression is often overlooked in patients with epilepsy.

The chief medical officer at SK Life Science discussed what makes cenobamate unique, as well as what current studies have discovered.

The pediatric psychologist at Children’s Medical Center discussed what her team does to assess patients in the clinic when something comes up as a result of a patient’s screening.

The Director of the Epilepsy Division at Mayo Clinic in Phoenix discussed the issue of driving when withdrawing patients off seizure medication either because of treatment, remission or surgical intervention.

The section chief of pediatric neurology at Nationwide Children’s Hospital discussed cannabidiol's potential in the Lennox-Gastaut syndrome space.

WVE-210201 was granted both Orphan Drug and Rare Pediatric Disease designations from the FDA, as well as Orphan Drug status in the European Commission.

Neurology News Network for the week of December 1, 2018.

The agent is designed to target the tau “seeds” that spread throughout the brain over the progression of the disease, with its first clinical assessment expected to occur in early 2019.

Despite smaller trials suggesting some benefit, a trial of more than 3000 patients has demonstrated no differences between placebo and fluoxetine 6 months post-stroke.

The Senior Medical Director of Eli Lilly and Company spoke to lasmiditan and the clinical impact the investigational therapy could have for patients with acute migraine.

In quick cognitive tests routinely used in primary care, misclassification by at least 1 assessment occured in 36.7% participants, whereas only 1.7% were misclassified by all 3.

The Director of the Stanford Epilepsy Center discussed the work that’s left to be done in the field of epilepsy.

The non-invasive vagus nerve stimulator’s OK marks the first approval for cluster headache of any kind.

The instructor in neurology at Beth Israel Deaconess Medical Center spoke about what clinicians can do right now to mitigate the risk of SUDEP and the myriad of options for them to utilize.

The SVP and chief strategy and development officer at Aquestive Therapeutics discussed the hope to provide both patients and providers with a more favorable, and still efficacious, option for seizure clusters.

Recent data has shown that a start low, go slow approach with cenobamate may mitigate the risk of drug reaction with eosinophilia and systemic symptoms syndrome.

The Director of the UCLA Seizure Disorder Center explained the importance of referring patients with seizures to epilepsy centers.

The largest and longest prospective neuromodulation trial in the field of epilepsy showed about a 75% response rate with patients achieving at least a 50% reduction in seizures.

The Director of the Stanford Epilepsy Center discussed the current activities of epileptologists and considered how this might change in the near future, given advancing technology.

Regulatory action is expected to be made by May 2019. The therapy previously received a Breakthrough Therapy designation from the FDA.

The associate professor of neurology at the University of Rochester shared some of her advice for treating patients with epilepsy and focusing on the patient.

The director of the Epilepsy Program at Children’s Hospital of Philadelphia spoke about the long-awaited advancement brought on by cannabidiol for Dravet syndrome.

This novel dosage form of diazepam had comparable times to maximal concentration in both 2-hour and 4-hour timeframes.